Industry

Multifaceted national initiative invites Americans to share stories of science’s impact and challenge misinformation ST. LOUIS–(BUSINESS WIRE)–Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every day, in the moments that matter most. From the medicine that … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that will circle the venue (Convene 22 Bishopsgate) on Nov. 11-12 to spotlight Gilead Sciences’ greed and refusal to make its breakthrough HIV prevention drug lenacapavir truly affordable … [Read more…]

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line of systemic therapy. The Company submitted the confirmatory Phase 3 TELLOMAK 3 protocol to the FDA, which completed its review with no further comments, … [Read more…]

TOKYO–(BUSINESS WIRE)–Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. … [Read more…]

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination well-tolerated: No grade 3 or higher treatment-related adverse events and no treatment-related discontinuations ECLIPSE registrational program evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta fully … [Read more…]

NEW ORLEANS–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many driven … [Read more…]

NEW YORK–(BUSINESS WIRE)–As the government shutdown continues to disrupt funding for education and workforce programs, Stepful, recently named the #1 EdTech company in the U.S. by TIME Magazine and Statista, announced it will continue offering free healthcare career training for military families. Federal programs that typically cover the cost of training for military spouses, active-duty … [Read more…]

Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in AI-powered cardiovascular diagnostics, today announced new groundbreaking clinical data presented at the American Heart Association (AHA) Scientific Sessions 2025. Among the studies highlighted was a late-breaking featured science presentation, published … [Read more…]

NEW YORK–(BUSINESS WIRE)–ByHeart, a next-generation baby nutrition company, announced today that, out of an abundance of caution, it has chosen to voluntarily recall two batches of ByHeart Whole Nutrition Infant Formula following notification from the U.S. Food and Drug Administration (FDA) of a broader ongoing investigation into a recent outbreak of infant botulism. Infant botulism … [Read more…]

Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable to placebo Enlicitide may help address unmet needs in ASCVD, a key driver of the ongoing cardiovascular (CV) epidemic RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the … [Read more…]